Oppenheimer Reiterates VBI Vaccines (VBIV) at Outperform, ACIP Recommendation Sets Stage for PreHevbrio Coverage
Tweet Send to a Friend
Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $8.00 price target on VBI Vaccines (NASDAQ: VBIV), following announcement of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
